Email updates

Keep up to date with the latest news and content from BMC Medical Imaging and BioMed Central.

Open Access Highly Accessed Case report

The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I

Patrick Schöffski16*, Christophe M Deroose2, Olivier Gheysens2, Nele Lips2, Koen Slabbaert3, Ben Vancleynenbreugel3, Philippe Moerman4 and Willy E Peetermans5

Author Affiliations

1 General Medical Oncology, UZ Leuven, Leuven, Belgium

2 Nuclear Medicine, UZ Leuven, Leuven, Belgium

3 Urology, UZ Leuven, Leuven, Belgium

4 Pathology, UZ Leuven, Leuven, Belgium

5 General Internal Medicine, UZ Leuven, Leuven, Belgium

6 Department of General Medical Oncology, University Hospitals Leuven, Laboratory of Experimental Oncology, Division of Oncology, Leuven Cancer Institute, Catholic University Leuven, Herestraat 49, Leuven B-3000, Belgium

For all author emails, please log on.

BMC Medical Imaging 2014, 14:19  doi:10.1186/1471-2342-14-19

Published: 29 May 2014



FDG-PET/CT is part of the standard diagnostic management of a patients with a large variety of common and less common malignant tumors, based on the increased glucose metabolism within tumors.

Case presentation

A hybrid fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) was performed in a neurofibromatosis patient to rule out relapse of malignant peripheral nerve sheet tumor. The scan revealed non-malignant neurofibromas, a testis seminoma and hypermetabolic syphilitic granulomata.


This case stresses the need to rule out infectious diseases when atypical hypermetabolic lesions are present.

Syphilis; PET; Fluorodeoyglucose; Neurofibromatosis; Testicular seminoma